Toxic cardiopathies

Acta Clinica Belgica

Volumn 60, Issue 5, 2005, Pages 293-300

  Van Camp, G ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Cardiopathies Drug and toxic cardiopathy; Valvulopathies

Indexed keywords

ALCOHOL; ANOREXIGENIC AGENT; ANTHRACYCLINE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIAC GLYCOSIDE; CHLOROQUINE; COBALT; COCAINE; CYCLOPHOSPHAMIDE; DIDANOSINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DOXORUBICIN; ERGOTAMINE; FENFLURAMINE; LEAD; MERCURY; METHYSERGIDE; MITOXANTRONE; PERGOLIDE; PHENTERMINE; TOXIC SUBSTANCE; TRASTUZUMAB; UNINDEXED DRUG; VITAMIN B GROUP; ZIDOVUDINE;

ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLIC CARDIOMYOPATHY; AORTA VALVE DISEASE; AUTONOMIC NEUROPATHY; CARDIOMYOPATHY; CARDIOTOXICITY; CONFERENCE PAPER; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DEATH; DRUG FATALITY; DRUG INDUCED DISEASE; DYSPNEA; FEVER; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART TAMPONADE; HEMORRHAGIC MYOCARDITIS; HUMAN; HYPERTENSION; HYPOTENSION; HYPOXIA; LUNG FIBROSIS; MITRAL VALVE DISEASE; MYOCARDIAL DEPRESSION; MYOCARDIAL DISEASE; MYOCARDITIS; PATIENT MONITORING; PROGNOSIS; PULMONARY HYPERTENSION; PULMONARY VALVE DISEASE; QT PROLONGATION; RAYNAUD PHENOMENON; RETINOIC ACID SYNDROME; RISK FACTOR; ST SEGMENT ELEVATION; T WAVE INVERSION; TOXIC CARDIOMYOPATHY; TRICUSPID VALVE DISEASE; VALVULAR HEART DISEASE; CHEMICALLY INDUCED DISORDER; DRUG TOXICITY; REVIEW;

ANTINEOPLASTIC AGENTS; CARDIOMYOPATHIES; CARDIOMYOPATHY, ALCOHOLIC; CARDIOMYOPATHY, DILATED; DRUG TOXICITY; HEART VALVE DISEASES; HUMANS;

EID: 33644816320     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2005.047     Document Type: Conference Paper

References (81)

1. Report of the 1995 WHO/ISFC Task force on the definition and classification of cardiomyopathies. Circulation 1996; 93: 841-2.
2. Dec, Fuster V. Medical progress: idiopathic dilated cardiomyopathy. N Engl J Med 1994; 331: 1564-75.
3. Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ. Valve disease associated with Ergot Alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 1992; 117: 50-2.
4. Connolly HM, Crary JL, Mc Goon MD, Hensrud DD, Edwards BS, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581-8.
5. Van Camp G, Flamez A, Cosyns B et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363: 1179-83.
6. Rothman RB, Bauman MH, Savage JE, Rauser L, Mc Bride A, Hufeisen SJ, Roth BL. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000; 102: 2836-41.
7. McKenna CJ, Codd MB, McCann HA, Sugrue DD. Alcohol consumption and idiopathic dilated cardiomyopathy: a case control study. Am Heart J 1998; 135: 833-7.
8. Crawford MH, DiMarco JP, Paulus WJ. Cardiology. 2° Edition, Mosby 2004.
9. Vital and Health Statistics. Hyattsville, MD: U.S. Department of Health and Human Services. Centers for Disease Control and Prevention, October 1995; 13 (122).
10. Fauchier L, Babuty D, Poret P, et al. Comparison of longterm outcome of alcoholic and idiopathic dilated cardiomyopathy. Eur Heart J 2000; 21: 306-14.
11. McKenna CJ, Codd MB, McCann HA, et al. Alcohol consumption in idiopathic dilated cardiomyopathy: a case control study. Am Heart J 1998; 135: 833-7.
12. Gavazzi A, De Maria R, Parolini M, et al, on behalf of the Italian Multicenter Cardiomyopathy Study Group (SPIC). Alcohol abuse and cardiomyopathy in men. Am J Cardiol 2000; 85: 1114-8.
13. Fernandez-Sola J, Estruch R, Nicolas J-M, et al. Comparison of alcoholic cardiomyopathy in women versus men. Am J Cardiol 1997; 80: 481-5.
14. Kupari M, Koskinen P, Suokas A, et al. Left ventricular filling impairment in asymptomatic chronic alcoholics. Am J Cardiol 1990; 66: 1473-7.
15. Lazarevic, AM, Nakatani S, Nes¡kovic, AN, et al. Early changes in left ventricular function in chronic asymptomatic alcoholics: relation to the duration of heavy drinking. J Am Coll Cardiol 2000; 35: 1599-606.
16. Askanas A, Udoshi M, Sadjadi SA. The heart in chronic alcoholism: a noninvasive study. Am Heart J 1980; 99: 9-16.
17. Silberbauer K, Juhasz M, Ohrenberger G, et al. Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in young alcoholics. Cardiology 1988; 75: 431-9.
18. Mathews EC, Gradin JM, Henry WL, et al. Echocardiographic abnormalities in chronic alcoholics with and without overt congestive heart failure. Am J Cardiol 1981; 47: 570-8.
19. Fernandez-Sola J, Nicolas JM, Para JC, et al. Diastolic function impairment in alcoholics. Alcohol Clin Exp Med 2000; 24: 1830-5.
20. Piano MR. Alcoholic cardiomyopathy. Indicence, clinical characteristics and pathophysiology. Chest 2002; 121: 1638-50.
21. Hibbs RG, Ferrans VJ, Black WC, et al. Alcoholic cardiomyopathy: an electron microscopic study. Am Heart J 1965; 69: 766-71.
22. Capasso JM, Li P, Guideri G. Myocardial mechanical, biochemical and structural alterations induced by chronic ethanol ingestion in rats. Circ Res 1992; 71: 346-56.
23. Chen DB, Wang L, Wang PH. Insulin-like growth factor I retards apoptotic signaling induced by ethanol in cardiomyocytes in ethanol dependent rats. Alcohol Alcoholism 1994; 29: 283-93.
24. Segel LD, Rendig SV, Choquet Y, et al. Effects of chronic graded ethanol consumption on the metabolism, ultrastructure, and mechanical function of the rat heart. Cardiovasc Res 1975; 9: 649-63.
25. Sarma JS, Ikeda S, Fischer R, et al. Biochemical and contractile properties of heart muscle after prolonged alcohol administration. J Mol Cell Cardiol 1976; 8: 951-72.
26. Alexander CS. Electron microscopic observations in alcoholic heart muscle disease. Br Heart J 1967; 29: 200-6.
27. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999; 79: 215-62.
28. Meehan J, Piano MR, Solaro RJ, et al. Heavy long-term ethanol consumption induces an α- to β-myosin heavy chain isoforms transition in rat. Basic Res Cardiol 1999; 94: 481-8.
29. Piano MR, Schwertz DW, Solaro RJ, et al. Effect of pimobenden and isoproterenol in the alcoholic myocardium. J Cardiovasc Pharmacol 1999; 33: 237-42.51
30. Wu S, White R, Eikman-Cofflet J, et al. The preventive effect of verapamil on ethanol-induced cardiac depression: phosphorus-31 nuclear magnetic resonance and high-pressure liquid chromatography studies of hamsters. Circulation 1987; 75: 1058-64.
31. Guppy LJ, Littleton JM. Binding characteristics of the calcium channel antagonist [3H]nitrendipine in tissues from ethanol dependent rats. Alcohol Alcoholism 1994; 29: 283-93.
32. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy. Diagnosis, pathogenesis and management. Circulation 2004; 109: 3122-31.
33. Myers C. Role of iron in anthracycline action. In: Hacker M, Lazo J, Tritton T, eds. Organ Directed Toxicities of Anticancer Drugs. Boston, Mass: Martinus Nijhoff; 1988:17-30.
34. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003; 97: 2869-79.
35. Robin L Jones, Gerald J Berry, Robert D Rubens, and David W Miles. Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin. Lancet Oncol; 5: 575-77.
36. Gill PS, Espina BM, Muggia F, et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol. 1995; 13: 996-1003.
37. Muggia FM. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs. 1997; 54: 22-9.
38. Von Hoff DD. Phase I trials of dexrazoxane and other potential applications for the agent. Semin Oncol. 1998; 25: 31-6.
39. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. Pharmacol Rev 2004; 56: 185-229.
40. Benjamin RS. Rationale for the use of mitoxantrone in the older patient: cardiac toxicity. Semin Oncol. 1995; 22: 11-3.
41. Dow E, Schulman H, Agura E. Cyclophosphamide cardiac injury mimicking acute myocardial infarction. Bone Marrow Transplant. 1993; 12: 169-72.
42. Steinherz LJ, Steinherz PG, Mangiacasale D, et al. Cardiac changes with Cyclophosphamide. Med Pediatr Oncol. 1981; 9: 417-22.
43. Gottdiener JS, Appelbaum FR, Ferrans VJ, et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy.
44. Arch Intern Med. 1981; 141:758-63.
45. Quezado ZM, Wilson WH, Cunnion RE, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993; 118: 31-6.
46. Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today (Bare). 2003;39(suppl C):1-16.
47. Albanell J, Baselga J. Systemic therapy emergencies. Semin Oncol 2000; 27: 347-361.
48. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neuoncogene. Science. 1987; 235: 177-82.
49. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002; 20: 1215-21.
50. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol. 2004; 22: 322-9.
51. Ewer MS, Gibbs HR, Swafford J, et al. Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic orsequential stress, or surveillance artifact? Semin Oncol. 1999; 26: 96-101.
52. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997; 337: 1021-28.
53. Tallman MS, Andersen JW, Schiffer CA, et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood. 2000; 95: 90-5.
54. Benjamin R. The schedule dependency of the cardiotoxicity of adriamycin: its relevance to pharmacokinetic parameters. In: Muggia F, ed. Cancer Treatment and the Heart. Baltimore, Md: The Johns Hopkins University Press; 1992:278.
55. Schmidinger M, Steger GG, Wenzel C, et al, for the Austrian Renal Cell Carcinoma Study Group. Sequential administration of interferon gamma and interleukin-2 in metastatic renal cell carcinoma: results of a phase II trial. Cancer Immunol Immunother. 2000; 49: 395-400.
56. Meinardi MT, van der Graaf WTA, van Veldhuisen DJ, et al. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev 1999; 25: 237-47.
57. Takenaka K, Kuwada Y, Sonoda M et al. Anthracycline-induced cardiomyopaties evaluated by tissue Doppler trackingsystem and strain rate imaging. J Cardiol 2001; 37 Suppl 1: 129-32.
58. Weesner KM, Bledsoe M, Chauvenet A, et al. Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer. 1991; 68: 435-8.
59. Klewer SE, Goldberg SJ, Donnerstein RL, et al. Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. J Am Coll Cardiol. 1992; 19: 394-401.
60. Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997; 96: 2641-8.
61. Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing associated cardiomyopathy: sequential stress and response to ACE-inhibitors and Carvedilol therapy. J Card Failure. 2003; 9: 383.
62. Lenihan DJ, Tong AT, Woods M, et al. Withdrawal of ACE-inhibitors and beta-blockers in chemotherapy induced heart failure leads to severe adverse cardiovascular events. Circulation. 2003; 108(suppl IV):IV-665.
63. Office of Applied Studies. Year-end 1999 emergency department data from the Drug Abuse Warning Network. Rockville, Md.: Substance Abuse and Mental Health Services Administration, August 2000. (DHHS publication no. (SMA) 00-3462.)
64. Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med, 2001; 345: 351-8.
65. Virmani R, Robinowitz M, Smialek JE, Smyth DF. Cardiovascular effects of cocaine: an autopsy study of 40 patients. Am Heart J 1988; 115: 1068-76.
66. Mao JT, Zhu LX, Sharma S, et al. Cocaine inhibits human endothelial cell IL-8 production: the role of transforming growth factor-beta. Cell Immunol 1997; 181: 38-43.
67. Besse S, Assayag P, Latour C, et al. Molecular characteristics of cocaine-induced cardiomyopathy in rats. Eur J Pharmacol 1997; 338: 123-9.
68. Xiao Y, He J, Gilbert RD, Zhang L. Cocaine induces apoptosis in fetal myocardial cells through a mitochondria-dependent pathway. J Pharmacol Exp Ther 2000; 292: 8-14.
69. Perreault CL, Hague NL, Morgan KG, Allen PD, Morgan JP. Negative inotropic and relaxant effects of cocaine on myopathic human ventricular myocardium and epicardial coronary arteries in vitro. Cardiovasc Res 1993; 27: 262-8.
70. Huang L, Woolf JH, Ishiguro Y, Morgan JP. Effect of cocaine and methylecgonidine on intracellular Ca2+ and myocardial contraction in cardiac myocytes. Am J Physiol 1997; 273: H893-H901.
71. Wiener RS, Lockhart JT, Schwartz RG. Dilated cardiomyopathy and cocaine abuse: report of two cases. Am J Med 1986; 81: 699-701.
72. Bertolet BD, Freund G, Martin CA, Perchalski DL, Williams CM, Pepine CJ. Unrecognized left ventricular dysfunction in an apparently healthy cocaine abuse population. Clin Cardiol 1990; 13: 323-8.
73. Chokshi SK, Moore R, Pandian NG, Isner JM. Reversible cardiomyopathy associated with cocaine intoxication. Ann Intern Med 1989;111:1039-40.
74. Munroe DS, Allen P, Cox AR. Mitral regurgitation occuring during methysergide (Sansert) therapy. Can Med Assoc J 1969; 101: 62-5.
75. Bana DS, MacNeal PS, LeCompte PM, Shah Y, Graham JR. Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J 1974; 88: 640-55.
76. Misch KA. Development of heart valve lesions during methysergide therapy. Br Med J 1974; 2: 365-6.
77. Hauck AJ, Edwards WD, Danielson GK, Mullany CJ, Bresnahan DR. Mitral and aortic valve disease associated with ergotamine therapy for migraine: report of two cases and review of the literature. Arch Pathol Lab Med 1990; 114: 62-4.
78. Seghatol FF, Rigolin VH. Appetite suppressants and valvular heart disease. Curr Opin Cardiol 2002; 17: 486-92.
79. Pritchet AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002; 77: 1280-6.
80. Robiolo PA, Rigolin VH, Wilson JS, Harrison JK, Sanders LL, Bashmore TM, Feldman JM. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995; 92: 790-5.
81. Fitzgerald LW, Burn TC, Brown BS et al. Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine. Mol Pharm 2000; 57: 75-81.